MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.030
+0.020
+1.98%
Closed 17:43 12/01 EST
OPEN
1.020
PREV CLOSE
1.010
HIGH
1.050
LOW
1.000
VOLUME
90.27K
TURNOVER
0
52 WEEK HIGH
1.850
52 WEEK LOW
0.6501
MARKET CAP
64.28M
P/E (TTM)
-1.6919
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CLSD last week (1127-1201)?
Weekly Report · 2h ago
Weekly Report: what happened at CLSD last week (1120-1124)?
Weekly Report · 11/27 09:58
Weekly Report: what happened at CLSD last week (1113-1117)?
Weekly Report · 11/20 09:58
Clearside Biomedical: Buy Recommendation Based on Positive Clinical Trials and Value Inflection Opportunities
TipRanks · 11/14 20:25
HC Wainwright & Co. Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Benzinga · 11/14 11:48
Promising Developments and Financial Stability Bolster Buy Rating for Clearside Biomedical
Analyst andreas argyrides from wedbush remains neutral on clearside biomedical and has a buy rating on the stock. Jmp securities also reiterated a buy rating on the healthcare sector company. Clsd is developing drug therapies to treat blinding diseases of the eye.
TipRanks · 11/14 11:46
Analysts’ Top Healthcare Picks: Arcellx Inc (ACLX), Clearside Biomedical (CLSD)
3 analysts have reiterated buy ratings on 3 healthcare sector stocks. Arcellx inc, clearside biomedical and eyenovia are among the companies with bullish sentiments. H.c. Wainwright maintained a buy rating on arcellx inc today and reiterated a buy rating on clearsid biomedical.
TipRanks · 11/14 11:30
Clearside Biomedical Earns Buy Rating Amid Successful Clinical Trials and Promising Partnerships: An Analysis by Jonathan Wolleben
TipRanks · 11/14 05:26
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve vision in patients with sight-threatening eye diseases. It is focused on developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector, and it also partners with companies developing other ophthalmic therapeutics to be administered using its SCS injection platform. Its lead product candidate, XIPERE, is a preservative-free suspension of the corticosteroid triamcinolone acetonide (TA), formulated for administration through suprachoroidal injection. Its pipeline includes CLS-AX, CLS-301 and Gene Therapy.

Webull offers Clearside Biomedical Inc stock information, including NASDAQ: CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.